NAT10-mediated N4-acetylcytidine (ac4C) modification of PIK3R2 mRNA promotes malignant progression of glioblastoma
Year: 2025
Type: article
Language: en
Topic: RNA modifications and cancer
Authors and affiliations:
raw_author_name: Xiannan Meng
raw_affiliation_strings: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Tao Dong
raw_affiliation_strings: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Jiayu Xu
raw_affiliation_strings: Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China
raw_author_name: Kaiwen Tian
raw_affiliation_strings: Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Wendong Yang
raw_affiliation_strings: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Zixuan Liu
raw_affiliation_strings: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Yongjing Qian
raw_affiliation_strings: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Dingding Liu
raw_affiliation_strings: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Changxiu Chen
raw_affiliation_strings: Department of Pediatrics, The Affiliated Huaihai Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Jin Bai
raw_affiliation_strings: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China. bj@xzhmu.edu.cn
Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. bj@xzhmu.edu.cn
Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. bj@xzhmu.edu.cn
Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Hongmei Yong
raw_affiliation_strings: Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China. Ha2280@126.com
Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China
raw_author_name: Xiaojin Wu
raw_affiliation_strings: Cancer Center, Xuzhou Central Hospital, Southeast University, Xuzhou, Jiangsu, China. xiaojinwuxz@163.com
Department of Radiation Oncology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China. xiaojinwuxz@163.com
Cancer Center, Xuzhou Central Hospital, Southeast University, Xuzhou, Jiangsu, China
Department of Radiation Oncology, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China
raw_author_name: Zhigang Shen
raw_affiliation_strings: Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China. szgai4c@163.com
Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. szgai4c@163.com
Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China